These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23160921)

  • 1. Characterization and stabilization of recombinant human protein pentraxin (rhPTX-2).
    Liu J; Blasie CA; Shi S; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2013 Mar; 102(3):827-41. PubMed ID: 23160921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions.
    Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR
    J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA.
    Shi S; Liu J; Joshi SB; Krasnoperov V; Gill P; Middaugh CR; Volkin DB
    J Pharm Sci; 2012 Jun; 101(6):1969-84. PubMed ID: 22411527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ionic strength and pH on the physical and chemical stability of a monoclonal antibody antigen-binding fragment.
    Wang T; Kumru OS; Yi L; Wang YJ; Zhang J; Kim JH; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2013 Aug; 102(8):2520-37. PubMed ID: 23824562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preformulation characterization of an aluminum salt-adjuvanted trivalent recombinant protein-based vaccine candidate against Streptococcus pneumoniae.
    Iyer V; Hu L; Liyanage MR; Esfandiary R; Reinisch C; Meinke A; Maisonneuve J; Volkin DB; Joshi SB; Middaugh CR
    J Pharm Sci; 2012 Sep; 101(9):3078-90. PubMed ID: 22538529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening for stability and compatibility conditions of recombinant human epidermal growth factor for parenteral formulation: effect of pH, buffers, and excipients.
    Santana H; González Y; Campana PT; Noda J; Amarantes O; Itri R; Beldarraín A; Páez R
    Int J Pharm; 2013 Aug; 452(1-2):52-62. PubMed ID: 23624083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation development of a plant-derived H1N1 influenza vaccine containing purified recombinant hemagglutinin antigen.
    Iyer V; Liyanage MR; Shoji Y; Chichester JA; Jones RM; Yusibov V; Joshi SB; Middaugh CR
    Hum Vaccin Immunother; 2012 Apr; 8(4):453-64. PubMed ID: 22370514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of solvent environment on the conformation and stability of human polyclonal IgG in solution.
    Szenczi A; Kardos J; Medgyesi GA; Závodszky P
    Biologicals; 2006 Mar; 34(1):5-14. PubMed ID: 16168667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preformulation study of highly purified inactivated polio vaccine, serotype 3.
    Qi W; Zeng Y; Orgel S; Francon A; Kim JH; Randolph TW; Carpenter JF; Middaugh CR
    J Pharm Sci; 2014 Jan; 103(1):140-51. PubMed ID: 24282078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Native-state solubility and transfer free energy as predictive tools for selecting excipients to include in protein formulation development studies.
    Banks DD; Latypov RF; Ketchem RR; Woodard J; Scavezze JL; Siska CC; Razinkov VI
    J Pharm Sci; 2012 Aug; 101(8):2720-32. PubMed ID: 22648863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of a recombinant human epidermal growth factor parenteral formulation through freeze-drying.
    Santana H; Sotolongo J; González Y; Hernández G; Chinea G; Gerónimo H; Amarantes O; Beldarraín A; Páez R
    Biologicals; 2014 Nov; 42(6):322-33. PubMed ID: 25190208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H1N1 influenza virus-like particles: physical degradation pathways and identification of stabilizers.
    Kissmann J; Joshi SB; Haynes JR; Dokken L; Richardson C; Middaugh CR
    J Pharm Sci; 2011 Feb; 100(2):634-45. PubMed ID: 20669328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structure, stability, and complex behavior of recombinant human gelatins.
    Thyagarajapuram N; Olsen D; Middaugh CR
    J Pharm Sci; 2007 Dec; 96(12):3363-78. PubMed ID: 17518362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid, three-step process for the preformulation of a recombinant ricin toxin A-chain vaccine.
    Peek LJ; Brey RN; Middaugh CR
    J Pharm Sci; 2007 Jan; 96(1):44-60. PubMed ID: 16998874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal buffer systems for a newly glycosylated recombinant human interferon-β with biophysical stability and DoE approaches.
    Kim NA; Song K; Lim DG; Hada S; Shin YK; Shin S; Jeong SH
    Eur J Pharm Sci; 2015 Oct; 78():177-89. PubMed ID: 26215462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/deuterium-exchange mass spectrometry.
    Manikwar P; Majumdar R; Hickey JM; Thakkar SV; Samra HS; Sathish HA; Bishop SM; Middaugh CR; Weis DD; Volkin DB
    J Pharm Sci; 2013 Jul; 102(7):2136-51. PubMed ID: 23620222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody.
    Bond MD; Panek ME; Zhang Z; Wang D; Mehndiratta P; Zhao H; Gunton K; Ni A; Nedved ML; Burman S; Volkin DB
    J Pharm Sci; 2010 Jun; 99(6):2582-97. PubMed ID: 20039394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability.
    Chaudhuri R; Cheng Y; Middaugh CR; Volkin DB
    AAPS J; 2014 Jan; 16(1):48-64. PubMed ID: 24174400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating interactions of the pentraxins serum amyloid P component and C-reactive protein by mass spectrometry.
    Aquilina JA; Robinson CV
    Biochem J; 2003 Oct; 375(Pt 2):323-8. PubMed ID: 12892563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preformulation Characterization, Stabilization, and Formulation Design for the Acrylodan-Labeled Glucose-Binding Protein SM4-AC.
    Sahni N; Chaudhuri R; Hickey JM; Manikwar P; D'Souza A; Metters A; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2017 May; 106(5):1197-1210. PubMed ID: 28088457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.